EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis
K Mankia, HJ Siddle, A Kerschbaumer… - Annals of the …, 2021 - ard.bmj.com
Background Despite growing interest, there is no guidance or consensus on how to conduct
clinical trials and observational studies in populations at risk of rheumatoid arthritis (RA) …
clinical trials and observational studies in populations at risk of rheumatoid arthritis (RA) …
Macrophage's role in solid tumors: two edges of a sword
A Jahandideh, M Yarizadeh… - Cancer Cell …, 2023 - Springer
The tumor microenvironment is overwhelmingly dictated by macrophages, intimately
affiliated with tumors, exercising pivotal roles in multiple processes, including angiogenesis …
affiliated with tumors, exercising pivotal roles in multiple processes, including angiogenesis …
Immunomodulatory role of T helper cells in rheumatoid arthritis: a comprehensive research review
P Luo, P Wang, J Xu, W Hou, P Xu, K Xu… - Bone & joint …, 2022 - boneandjoint.org.uk
Rheumatoid arthritis (RA) is an autoimmune disease that involves T and B cells and their
reciprocal immune interactions with proinflammatory cytokines. T cells, an essential part of …
reciprocal immune interactions with proinflammatory cytokines. T cells, an essential part of …
Leukocyte adhesion: reconceptualizing chemokine presentation by glycosaminoglycans
GJ Graham, TM Handel, AEI Proudfoot - Trends in immunology, 2019 - cell.com
Recruitment of immune cells from the vasculature relies on the presentation of
glycosaminoglycan-bound chemokines on the luminal side of vascular endothelial cells …
glycosaminoglycan-bound chemokines on the luminal side of vascular endothelial cells …
The type I IFN signature as a biomarker of preclinical rheumatoid arthritis
J Lübbers, M Brink, LA van de Stadt… - Annals of the …, 2013 - ard.bmj.com
Objectives To validate the presence and demonstrate the clinical value of the type I
interferon (IFN)-signature during arthritis development. Method In 115 seropositive arthralgia …
interferon (IFN)-signature during arthritis development. Method In 115 seropositive arthralgia …
Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis
RA is a complex multifactorial chronic disease that transitions through several stages.
Multiple studies now support that there is a prolonged phase in early RA development …
Multiple studies now support that there is a prolonged phase in early RA development …
Preclinical Rheumatoid Arthritis Progress Toward Prevention.
K Mankia, P Emery - Arthritis & rheumatology, 2016 - search.ebscohost.com
The article discusses the study on rheutomatoid arthritis (RA) with regard to whether
localized autoimmunity is a crucial trigger in preclinical disease. The novel immunologic and …
localized autoimmunity is a crucial trigger in preclinical disease. The novel immunologic and …
Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis
Objective. IL-9 has been shown to be upregulated before the clinical onset of articular
disease in RA. The exact role of IL-9 and Th9 cells in RA, however, has not yet been …
disease in RA. The exact role of IL-9 and Th9 cells in RA, however, has not yet been …
Red blood cell distribution width: a potential laboratory parameter for monitoring inflammation in rheumatoid arthritis
Y He, C Liu, Z Zeng, W Ye, J Lin, Q Ou - Clinical rheumatology, 2018 - Springer
Correlation analysis of red blood cell distribution width (RDW) and C-reactive protein (CRP),
erythrocyte sedimentation rate (ESR), tumor necrosis factor α (TNF-α), interleukin (IL)-6, and …
erythrocyte sedimentation rate (ESR), tumor necrosis factor α (TNF-α), interleukin (IL)-6, and …
Anti-inflammatory activity of betalain-rich dye of Beta vulgaris: effect on edema, leukocyte recruitment, superoxide anion and cytokine production
RM Martinez, DT Longhi-Balbinot, AC Zarpelon… - Archives of Pharmacal …, 2015 - Springer
We have recently developed betalain-rich beetroot (Beta vulgaris) dye (betalain) to be used
in food products. Betalain (30–300 mg/kg) intraperitoneal (ip) treatment diminished …
in food products. Betalain (30–300 mg/kg) intraperitoneal (ip) treatment diminished …